Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 25:2:392.
doi: 10.1038/s42003-019-0642-9. eCollection 2019.

Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation

Mingzhu Wang #  1   2 , Junchao Wang #  1   2 , Rongjuan Wang #  3 , Shasha Jiao  3 , Shuang Wang  3 , Jinchao Zhang  3   4 , Min Zhang  1
Affiliations

Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation

Mingzhu Wang et al. Commun Biol. .

Abstract

Programmed cell death 1 (PD-1) is inhibitory receptor and immune checkpoint protein. Blocking the interaction of PD-1 and its ligands PD-L1/ L2 is able to active T-cell-mediated antitumor response. Monoclonal antibody-based drugs targeting PD-1 pathway have exhibited great promise in cancer therapy. Here we show that MW11-h317, an anti-PD-1 monoclonal antibody, displays high affinity for PD-1 and blocks PD-1 interactions with PD-L1/L2. MW11-h317 can effectively induce T-cell-mediated immune response and inhibit tumor growth in mouse model. Crystal structure of PD-1/MW11-h317 Fab complex reveals that both the loops and glycosylation of PD-1 are involved in recognition and binding, in which Asn58 glycosylation plays a critical role. The unique glycan epitope in PD-1 to MW11-h317 is different from the first two approved clinical PD-1 antibodies, nivolumab and pembrolizumab. These results suggest MW11-h317 as a therapeutic monoclonal antibody of PD-1 glycosylation-targeting which may become efficient alternative for cancer therapy.

Keywords: Cancer; Cancer immunotherapy; Structural biology.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The complex structure of MW11-h317 Fab bound to PD-1. The Fab fragment of MW11-h317 and PD-1 are shown as cartoon (MW11-h317 Fab heavy chain in green, light chain in cyan, PD-1 in gray). The glycans in PD-1 are shown as sticks in yellow
Fig. 2
Fig. 2
Loops of PD-1 in MW11-h317 Fab recognition. a The C′D loop, BC loop, and FG loop of PD-1 are represented in skyblue, pink, and lime, respectively. The CDR1, CDR2, and CDR3 loops of MW11-h317 light chain (LCDR1, LCDR2, LCDR3) are shown in yellow, blue, and magenta, respectively. The CDR1, CDR2, and CDR3 loops of MW11-h317 heavy chain (HCDR1, HCDR2, HCDR3) are represented in red, deep teal, and orange, respectively. Detailed interactions of MW11-h317 Fab binding to the PD-1 BC loop b, C′D loop c, and FG loop d are presented. Residues involved in the hydrogen bond interaction are shown as sticks and labeled. Hydrogen bonds are shown as dashed red lines
Fig. 3
Fig. 3
Glycosylation of PD-1. a N-glycosylation of N49, N58, and N116 in PD-1. b Diagrammatic representation of N-link glycans of N58, where blue squares represent N-acetylglucosamines, red triangle is fucose, and green circles are mannose. c The Fo−Fc simulated annealing omit map of N-linked glycans of N58 contoured at 3.0σ. The stick model of glycans was superposed in the image. d Interactions between N-linked glycans of N58 and MW11-h317. The participating amino acid residues and glycans are shown with a stick model, with amino acids in MW11-h317 colored in green and glycans in PD-1 colored in yellow. Hydrogen bonds are indicated with magenta dashed lines
Fig. 4
Fig. 4
N-glycosylation of N58 participates in MW11-h317 recognition. A flow cytometric analysis of MW11-h317 binding to WT PD-1 or various glycosylation sites mutated proteins (N49A, N58A, N74A, and N116A) expressed on the cell surface of HEK 293 cells. Plasmids expressing WT PD-1 or mutant proteins fused with EGFP were used for transfection. Mock-transfected HEK 293 cells were used as negative control (NC)
Fig. 5
Fig. 5
Competitive binding of MW11-h317 Fab with PD-1 ligand PD-L1. a Superposition of the PD-1/MW11-h317 Fab complex structure with PD-1/PD-L1 complex structure (PDB ID: 4ZQK). MW11-h317 H chain is shown in green, L chain in cyan and PD-L1 in pink. PD-1 is shown as surface representation in gray. b Binding surface of PD-1 with MW11-h317 or PD-L1. The residues in contact with MW11-h317 are shown in green, whereas residues in contact with PD-L1 are shown in pink, and the overlapping residues bounded by both MW11-h317 and PD-L1 are shown in orange
Fig. 6
Fig. 6
Distinct blocking mechanism of MW11-h317 compared with nivolumab and pembrolizumab. a, b Competitive binding of MW11-h317 and nivolumab (PDB ID: 5WT9) with PD-1. MW11-h317 and nivolumab are shown in green and blue, respectively, and the overlapping residues bounded by both MW11-h317 and nivolumab are shown in cyan. c, d Competitive binding of MW11-h317 and pembrolizumab (PDB ID: 5GGS) with PD-1. MW11-h317 and pembrolizumab are shown in green and red, respectively, and the overlapping residues bounded by both MW11-h317 and pembrolizumab are shown in yellow. e Antibodies competitive ELISA indicated that MW11-h317 was partly competitive with nivolumab or pembrolizumab. n = 3 independent experiments; data are mean ± SEM
Fig. 7
Fig. 7
Comparable activities of MW11-h317 to nivolumab. a Affinities of MW11-h317 and nivolumab to PD-1. b MW11-h317 and nivolumab blocked the binding between PD-1 and PD-L1 (or PD-L2). c IL-2 or IFN-γ production in mixed lymphocytes stimulated by MW11-h317 and nivolumab. d Volumes and weights of subcutaneous xenograft tumors in PD-1 transgenic mice. Administration dose 10, 2, and 0.5 mg kg−1 indicated as 10, 2, and 0.5 following antibodies’ name (n = 8 mice/tumor experiments)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of Pd-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell-death. EMBO J. 1992;11:3887–3895. doi: 10.1002/j.1460-2075.1992.tb05481.x. - DOI - PMC - PubMed
    1. Chemnitz JM, et al. RNA fingerprints provide direct evidence for the inhibitory role of TGF beta and PD-1 on CD4(+) T cells in Hodgkin lymphoma. Blood. 2007;110:3226–3233. doi: 10.1182/blood-2006-12-064360. - DOI - PubMed
    1. Shimauchi T, et al. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4(+) T-cells in adult T-cell leukemia/lymphoma. Int. J. Cancer. 2007;121:2585–2590. doi: 10.1002/ijc.23042. - DOI - PubMed
    1. Dong HD, et al. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002;8:793–800. doi: 10.1038/nm730. - DOI - PubMed
    1. Yamazaki T, et al. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 2002;169:5538–5545. doi: 10.4049/jimmunol.169.10.5538. - DOI - PubMed

MeSH terms